Shelter Pharma Bags ₹0.1 Cr Order from Berlin International Company
Shelter Pharma received a ₹0.10 Cr export order from Berlin International Company for D3 CURE nutraceuticals. The order broadens its global nutraceutical customer base.
Value
₹0.10 Cr
From
Berlin International Company
Execution
mutually agreed timelines as per purchase order schedule
Shelter Pharma will participate in the Vishwa Ayurveda Parishad Exhibition in Jaipur on 17-18 September 2026. The company secured a stall to showcase its pharmaceutical and Ayurveda product portfolio.
Shelter Pharma Limited announced its 19th Annual General Meeting for September 29, 2026. The board also approved the regularisation of Ms. Vinita Shivraj Gadhvi as Independent Director.
Shelter Pharma Limited announced the regularization of Ms. Vinita Shivraj Gadhavi as a Non-Executive Independent Director. The Board also approved the notice for the 19th AGM.
Shelter Pharma Limited has successfully completed and dispatched an export order to Sudan. The contract, from Taha Drugs & Chemicals Co. Ltd, is valued at $1,44,000.
Shelter Pharma Limited launched SHELTIDIN DS, an Ayurvedic herbal cough spray, in the domestic market. The product is available on e-commerce platforms as of August 20, 2026.
Shelter Pharma Limited successfully completed and dispatched an export order worth USD 12,285 to Genet International in Bangladesh. This marks a milestone in the company's international growth.
Shelter Pharma Limited completed and dispatched an export order for vitamins to Taha Drugs & Chemicals Co. Ltd, Sudan. The contract was valued at USD 103,538.
Shelter Pharma Limited has appointed Ms. Vinita Shivraj Gadhvi as an Additional Independent Director for a five-year term. The Board also reconstituted its Corporate Social Responsibility Committee.
Shelter Pharma received international purchase orders from Genet International for veterinary feed supplements. The total value of these orders is USD 12,285.
Shelter Pharma received a ₹0.26 Crore purchase order from Al‑Saqr Agro for veterinary feed supplements, to be executed within two months. The contract adds to its order pipeline.
Shelter Pharma cancelled its H2 FY2026 Investor Conference Call scheduled for June 10, 2026. A revised date will be announced later, delaying management's performance update.
Shelter Pharma completed a ₹1.35 Crore export order for Taha Drugs & Chemicals. Dispatch to Sudan has commenced, marking successful contract execution and revenue realization.
Shelter Pharma received a manufacturing license renewal for Ayurvedic products from the Government of Gujarat. The license is valid until September 2030, ensuring uninterrupted operations.
Shelter Pharma reported zero deviation in utilizing ₹25.31 Crore raised via preferential warrant issues. Funds were fully deployed toward working capital requirements as approved.
Shelter Pharma reported a net profit of ₹9.03 Crore for the financial year ended March 31, 2026. The board also appointed CA Ismail Lakhani as internal auditor.
Shelter Pharma scheduled a Board Meeting for May 28, 2026, to approve audited financial results. The meeting covers performance for the half-year and full-year ended March 2026.
Shelter Pharma reports continuous positive customer feedback for its healthcare products across various platforms. This trend strengthens brand credibility and supports long-term growth prospects.
Shelter Pharma will participate in the iPHEX 2026 exhibition at Bharat Mandapam. This strategic move aims to enhance global visibility and explore new export opportunities.
Shelter Pharma successfully conducted a CME program in Patna attended by 32 doctors. The session strengthened product awareness and professional relationships within the medical fraternity.
Shelter Pharma launched FOLIMAN Folic Acid Tablets in international markets on May 11, 2026. This expansion into nutraceuticals aims to strengthen its global healthcare segment presence.
Shelter Pharma Limited has allotted 1,11,000 equity shares at Rs. 42.25 each following the conversion of warrants by a non-promoter investor. The company received Rs. 0.35 Crore as the remaining 75% exercise price. Consequently, the paid-up equity share capital increased to Rs. 16.84 Crore.
Shelter Pharma Ltd received repeat international purchase orders worth USD 84,450 (approx. ₹0.80 Crore) from Taha Drugs & Chemicals Co. Ltd. The order involves supplying D3 Cure and Joemega capsules. This development enhances the company's global footprint and contributes to revenue growth.
